FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer-Reference-Cited by-同舟云学术

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Published:2015-08-31 Issue:21 Volume:21 Page:4760-4766
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Beaver Julia A.,Amiri-Kordestani Laleh,Charlab Rosane,Chen Wei,Palmby Todd,Tilley Amy,Zirkelbach Jeanne Fourie,Yu Jingyu,Liu Qi,Zhao Liang,Crich Joyce,Chen Xiao Hong,Hughes Minerva,Bloomquist Erik,Tang Shenghui,Sridhara Rajeshwari,Kluetz Paul G.,Kim Geoffrey,Ibrahim Amna,Pazdur Richard,Cortazar Patricia

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation;Cancer Treatment Reviews;2024-11

2. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

3. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors;European Journal of Medicinal Chemistry;2024-09

4. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

5. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer;Breast Cancer Research and Treatment;2024-08-23